Cordis Launches 10,000-Patient Global Registry for SELUTION SLR Drug-Eluting Balloon
• Cordis has initiated the SELUTION Global Coronary Registry, which will track real-world outcomes of their sirolimus-eluting balloon in up to 10,000 patients worldwide for five years.
• The registry complements five ongoing randomized trials and builds on positive peripheral experience data, positioning SELUTION SLR as a next-generation technology that delivers sustained drug release without permanent implants.
• A distinguished steering committee of international interventional cardiologists will oversee the registry, including Dr. Ajay Kirtane from Columbia University as chairman.
SELUTION SLR Drug-Eluting Balloon Shows Exceptional 3-Year Patency Rates in Peripheral Artery Disease Trials
• Cordis's SELUTION SLR Drug-Eluting Balloon demonstrated remarkable 81.5% primary patency at 3 years in the Japan Trial, establishing it as the only sirolimus-eluting technology with core-lab adjudicated 3-year patency exceeding 80%.
• The SUCCESS PTA Study showed consistent effectiveness across 723 real-world patients, with freedom from clinically-driven target lesion revascularization reaching 91.1% overall at 12 months, including strong results in both claudicant and CLTI populations.
• The sirolimus MicroReservoir technology in SELUTION SLR offers advantages over paclitaxel-based alternatives, with investigators noting "unprecedented durability" and "unequivocal clinical benefits" for complex peripheral artery disease patients.
Endovascular Engineering Secures $42M Series B to Advance Novel Pulmonary Embolism Treatment
• Endovascular Engineering has raised $42 million in Series B funding, co-led by 415 Capital and S3 Ventures, to advance their Hēlo PE Thrombectomy System for treating pulmonary embolism.
• The company's innovative Hēlo Thrombectomy System combines powerful aspiration with mechanical clot disruption, delivering large-bore performance through a small-profile catheter for efficient clot removal.
• The funding will support completion of the ENGULF pivotal trial evaluating the Hēlo PE System, positioning the company to establish a new standard of care in mechanical thrombectomy for pulmonary embolism.
Akeso's Gumokimab (IL-17 mAb) Application Accepted for Psoriasis Treatment in China
• Akeso's gumokimab, an IL-17 targeting monoclonal antibody, has its NDA accepted by China's NMPA for treating moderate to severe plaque psoriasis.
• Clinical trials showed gumokimab's rapid efficacy, with PASI 75 response rates approaching 96% at week 12 and sustained improvement over 52 weeks.
• Safety profiles of gumokimab were comparable to placebo, indicating good tolerability, which addresses the need for safer psoriasis treatments.
• Akeso aims to meet diverse patient needs by combining gumokimab with other drugs like ebronucimab, enhancing their autoimmune disease product synergy.
© Copyright 2025. All Rights Reserved by MedPath